Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Multiple Doses of Tiprogrel in Healthy Subjects
NCT06584812Phase 1Completed
- Sponsor
- Tianjin Institute of Pharmaceutical Research
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taipugrel in acute coronary syndrome (ACS) and ischemic stroke, sponsored by Tianjin Institute of Pharmaceutical Research. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve and 4 more. Started Sep 2024; status: completed.
02
Drugs
taipugrel
03
Conditions
acute coronary syndrome (ACS)ischemic stroke
Beyond the preview
Go deeper on NCT06584812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06584812.